Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

Exclusion Criteria

• •Past history of surgical procedure experience related to BPH
• •Past history of taking 5-alpha reductase inhibitor(5-ARI) within 6 months before screening, or for more than 12 months regardless of the point of time
• •Past history of taking alpha blocker within 2 weeks before screening
• •Past history of acute urinary retention within 3 months before screening
• •Serum PSA ≥ 10 ng/ml (but, in the case of 4 ng/ml ≤ PSA \< 10 ng/ml, the patients can be included only if prostate cancer is excluded by prostate biopsy)
• •Anatomical abnormalities of lower urinary tracts(urethrostenosis, diverticulosis, bladder neck contracture)
• •Clinical status that affects voiding other than BPH(neurogenic bladder, Chronic Prostatitis/Chronic Pelvic Pain Syndrome, urinary infection, etc.)
• •Unstable and significant medical condition including below
• •* Unstable angina pectoris, myocardial infarction, cerebrovascular disease within 6 months before screening
• •* Past history of malignant tumor including skin basal cell carcinoma within 5 years before screening
• •* Medically uncontrollable diabetes mellitus, peptic ulcer disease
• •* Severe hepatic diseases
• •* Past history of renal failure or renal disease (serum creatinine \> 1.4mg/dl)
• •* Condition expected serious adverse event due to the investigational drug